At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 339 enrolled
Drug / intervention
Alogliptin and pioglitazone +2 moredrug
Likely dose
Alogliptin and pioglitazone 12.5mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter Study to Determine the Efficacy and Safety of SYR-322 When Used in Combination With Thiazolidine in Subjects With Type 2 Diabetes in Japan
In Brief
A Phase 3 clinical trial evaluating Alogliptin and pioglitazone and Pioglitazone for Type 2 Diabetes Mellitus. Completed, enrolled 339 participants.
Detailed Summary
The purpose of this study was to evaluate the efficacy and safety of alogliptin, once daily (QD) combined with a thiazolidine taken QD in type 2 diabetic patients with uncontrolled blood glucose.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 2 Diabetes Mellitus
Countries--
Collaborators--
Timeline
Phase 3CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartNov 2007
Primary CompletionOct 2008
First PostedMar 2011
TodayJul 2026
First PostedMar 18, 2011
Enrollment StartNov 1, 2007
Primary CompletionOct 1, 2008
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 15.3 years ago
Interventions
Alogliptin and pioglitazonedrug
Alogliptin 12.5mg, tablets, orally, once daily and Pioglitazone 15 or 30 mg, tablets orally once daily for up 12 weeks.
Alogliptin and pioglitazonedrug
Alogliptin 25 mg, tablets, orally, once daily and Pioglitazone 15 or 30 mg, tablets orally once daily for up 12 weeks.
Pioglitazonedrug
Pioglitazone 15 or 30 mg, tablets orally once daily for up 12 weeks.